Oskar Zakiyanov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oskar Zakiyanov has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Marta Kalousová
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
12 shared publications - Tomáš Zima
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine , Charles University and General University Hospita l , Prague , Czech Republic
9 shared publications Vladimír Tesař
Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
7 shared publications- Vladimir Tesar
General University Hospital, Charles University, Prague, Czech Republic
4 shared publications Jan Vachek
First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Department of Nephrology, Prague, CZECH REPUBLIC
3 shared publicationsMarta Kalousová
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
3 shared publications
Latest Publications
- Open Access
- 4 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2812
Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
Sodium glucose transporter type 2 (SGLT2) molecules are found in proximal tubules of the kidney, and perhaps in the brain or intestine, but rarely in any other tissue. However, their inhibitors, intended to improve diabetes compensation, have many more beneficial effects. They improve kidney and cardiovascular outcomes and decrease mortality. These benefits are not limited to diabetics but were also found in non-diabetic individuals. The pathophysiological pathways underlying the treatment success have been investigated in both clinical and experimental studies. There have been numerous excellent reviews, but these were mostly restricted to limited aspects of the knowledge. The aim of this review is to summarize the known experimental and clinical evidence of SGLT2 inhibitors’ effects on individual organs (kidney, heart, liver, etc.), as well as the systemic changes that lead to an improvement in clinical outcomes.
- 4 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2812
Open AccessSodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
Sodium glucose transporter type 2 (SGLT2) molecules are found in proximal tubules of the kidney, and perhaps in the brain or intestine, but rarely in any other tissue. However, their inhibitors, intended to improve diabetes compensation, have many more beneficial effects. They improve kidney and cardiovascular outcomes and decrease mortality. These benefits are not limited to diabetics but were also found in non-diabetic individuals. The pathophysiological pathways underlying the treatment success have been investigated in both clinical and experimental studies. There have been numerous excellent reviews, but these were mostly restricted to limited aspects of the knowledge. The aim of this review is to summarize the known experimental and clinical evidence of SGLT2 inhibitors’ effects on individual organs (kidney, heart, liver, etc.), as well as the systemic changes that lead to an improvement in clinical outcomes.
- 1 January 2021
- Published by Elsevier
- Vol. 105, 141-212
Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease
- 1 January 2021
- Published by Elsevier
- Vol. 105, 141-212
Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease
- 27 August 2019
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 68 (4) , 547-558
Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: A prospective observational cohort study
Sclerostin is a protein which is involved in bone metabolism and probably also in vessel wall function. This prospective observational cohort study evaluated the prognostic significance of sclerostin in hemodialysis (HD) patients. In total, 106 HD patients and 25 healthy controls participated in the study. HD patients were prospectively followed up for five years. Sclerostin was measured in serum using standard ELISA kits by Biomedica. Sclerostin concentrations in serum were higher in HD patients compared to the controls (89.2±40.3 pmol/l vs. 32.8±13.0 pmol/l, p84 pmol/l), HR (95 % CI): 2.577 (1.0002-10.207), p=0.04. When sclerostin was evaluated together with residual diuresis in Kaplan-Meier analysis the worst prognosis due to cardiovascular events was observed in the group with high sclerostin and zero residual diuresis compared to all other patients (p=0.007). In summary, serum sclerostin levels in HD patients were increased when compared to healthy subjects. High sclerostin levels were demonstrated as a risk factor for cardiovascular mortality. Further studies are required to clarify the pathophysiological mechanisms of sclerostin action in patients with renal failure before therapeutic measures can be established.
- 27 August 2019
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 68 (4) , 547-558
Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: A prospective observational cohort study
Sclerostin is a protein which is involved in bone metabolism and probably also in vessel wall function. This prospective observational cohort study evaluated the prognostic significance of sclerostin in hemodialysis (HD) patients. In total, 106 HD patients and 25 healthy controls participated in the study. HD patients were prospectively followed up for five years. Sclerostin was measured in serum using standard ELISA kits by Biomedica. Sclerostin concentrations in serum were higher in HD patients compared to the controls (89.2±40.3 pmol/l vs. 32.8±13.0 pmol/l, p84 pmol/l), HR (95 % CI): 2.577 (1.0002-10.207), p=0.04. When sclerostin was evaluated together with residual diuresis in Kaplan-Meier analysis the worst prognosis due to cardiovascular events was observed in the group with high sclerostin and zero residual diuresis compared to all other patients (p=0.007). In summary, serum sclerostin levels in HD patients were increased when compared to healthy subjects. High sclerostin levels were demonstrated as a risk factor for cardiovascular mortality. Further studies are required to clarify the pathophysiological mechanisms of sclerostin action in patients with renal failure before therapeutic measures can be established.
- Open Access
- 11 June 2019
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 44 (3) , 298-330
Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal
Matrix metalloproteinases (MMPs) are endopeptidases within the metzincin protein family that not only cleave extracellular matrix (ECM) components, but also process the non-ECM molecules, including various growth factors and their binding proteins. MMPs participate in cell to ECM interactions, and MMPs are known to be involved in cell proliferation mechanisms and most probably apoptosis. These proteinases are grouped into six classes: collagenases, gelatinases, stromelysins, matrilysins, membrane type MMPs, and other MMPs. Various mechanisms regulate the activity of MMPs, inhibition by tissue inhibitors of metalloproteinases being the most important. In the kidney, intrinsic glomerular cells and tubular epithelial cells synthesize several MMPs. The measurement of circulating MMPs can provide valuable information in patients with kidney diseases. They play an important role in many renal diseases, both acute and chronic. This review attempts to summarize the current knowledge of MMPs in the kidney and discusses recent data from patient and animal studies with reference to specific diseases. A better understanding of the MMPs’ role in renal remodeling may open the way to new interventions favoring deleterious renal changes in a number of kidney diseases.
- 11 June 2019
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 44 (3) , 298-330
Open AccessMatrix Metalloproteinases in Renal Diseases: A Critical Appraisal
Matrix metalloproteinases (MMPs) are endopeptidases within the metzincin protein family that not only cleave extracellular matrix (ECM) components, but also process the non-ECM molecules, including various growth factors and their binding proteins. MMPs participate in cell to ECM interactions, and MMPs are known to be involved in cell proliferation mechanisms and most probably apoptosis. These proteinases are grouped into six classes: collagenases, gelatinases, stromelysins, matrilysins, membrane type MMPs, and other MMPs. Various mechanisms regulate the activity of MMPs, inhibition by tissue inhibitors of metalloproteinases being the most important. In the kidney, intrinsic glomerular cells and tubular epithelial cells synthesize several MMPs. The measurement of circulating MMPs can provide valuable information in patients with kidney diseases. They play an important role in many renal diseases, both acute and chronic. This review attempts to summarize the current knowledge of MMPs in the kidney and discusses recent data from patient and animal studies with reference to specific diseases. A better understanding of the MMPs’ role in renal remodeling may open the way to new interventions favoring deleterious renal changes in a number of kidney diseases.
- Open Access
- 1 January 2019
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 65 (5-6) , 227-236
Matrix Metalloproteinases and Their Tissue Inhibitors: an Evaluation of Novel Biomarkers in ANCA-Associated Vasculitis
Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may play an important role in both inflammation with subsequent fibrosis and in repair and healing in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We evaluated the circulating levels of MMPs, including pregnancy-associated plasma protein A (PAPP-A), and TIMPs in patients with AAV. PAPP-A, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2 and selected parameters were measured in 100 AAV patients (36 patients with active disease and 64 patients in remission) and 34 healthy subjects. The levels of MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2, and PAPP-A in AAV were all found to be different to those of the controls. The MMP-7 and PAPP-A concentrations were increased in active disease in comparison to the controls (MMP-7: 13 ±.7 vs. 2 ± 0.6 ng/ml, PAPP-A: 14 ± 18 vs. 6.8 ± 2.6 ng/ml, both P < 0.005). The MMP-2 and TIMP-2 levels were increased in remission when compared to the controls (MMP-2: 242 ± 50 ng/ml vs. 212 ± 26 ng /ml, TIMP-2: 82 ± 14 ng/ml vs. 68 ± 93 ng/ml) and to the active AAV (MMP-2: 242 ± 50 vs. 219 ± 54 ng/ml, TIMP-2: 82 ± 14 ng/ml vs. 73 ± 15 ng/ml, all P < 0.005). MMP-3, MMP-7, TIMP-1, and PAPP-A correlated with serum creatinine. The serum levels of MMPs, TIMPs and PAPP-A are all altered in AAV. MMP-2, MMP-7 and TIMP-2 appear to be promising markers in distinguishing active AAV from remission. MMP-3, MMP-7, TIMP-1, and PAPP-A are associated with kidney function in AAV. Further studies are needed to delineate the exact roles of circulating MMPs, TIMPs and PAPP-A in patients with AAV.
- 1 January 2019
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 65 (5-6) , 227-236
Open AccessMatrix Metalloproteinases and Their Tissue Inhibitors: an Evaluation of Novel Biomarkers in ANCA-Associated Vasculitis
Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may play an important role in both inflammation with subsequent fibrosis and in repair and healing in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We evaluated the circulating levels of MMPs, including pregnancy-associated plasma protein A (PAPP-A), and TIMPs in patients with AAV. PAPP-A, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2 and selected parameters were measured in 100 AAV patients (36 patients with active disease and 64 patients in remission) and 34 healthy subjects. The levels of MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2, and PAPP-A in AAV were all found to be different to those of the controls. The MMP-7 and PAPP-A concentrations were increased in active disease in comparison to the controls (MMP-7: 13 ±.7 vs. 2 ± 0.6 ng/ml, PAPP-A: 14 ± 18 vs. 6.8 ± 2.6 ng/ml, both P < 0.005). The MMP-2 and TIMP-2 levels were increased in remission when compared to the controls (MMP-2: 242 ± 50 ng/ml vs. 212 ± 26 ng /ml, TIMP-2: 82 ± 14 ng/ml vs. 68 ± 93 ng/ml) and to the active AAV (MMP-2: 242 ± 50 vs. 219 ± 54 ng/ml, TIMP-2: 82 ± 14 ng/ml vs. 73 ± 15 ng/ml, all P < 0.005). MMP-3, MMP-7, TIMP-1, and PAPP-A correlated with serum creatinine. The serum levels of MMPs, TIMPs and PAPP-A are all altered in AAV. MMP-2, MMP-7 and TIMP-2 appear to be promising markers in distinguishing active AAV from remission. MMP-3, MMP-7, TIMP-1, and PAPP-A are associated with kidney function in AAV. Further studies are needed to delineate the exact roles of circulating MMPs, TIMPs and PAPP-A in patients with AAV.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i357-i358
SP035THE ROLE OF S100 PROTEINS AND MATRIX METALLOPROTEINASE AND THEIR INHIBITORSIN THE PATHOGENESIS OF LUPUS NEPHRITIS
INTRODUCTION AND AIMS: Proliferative lupus nephritis (LN) can potentially progress to renal failure. Little is known about the pathogenesis of proliferative processes that lead to irreversible glomerular damage. Metalloproteins especially matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) play an important role in maintaining homeostasis of extracellular matrix in the glomeruli. We examined the serum concentration of s-RAGE, EN-RAGE, HMGB1, PAPP-a, MMP-2, 3, 7, 9, TIMP-1, TIMP-2, S100A8, S100A9, to distinguish between the focal and diffuse form of proliferative LN.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i357-i358
SP035THE ROLE OF S100 PROTEINS AND MATRIX METALLOPROTEINASE AND THEIR INHIBITORSIN THE PATHOGENESIS OF LUPUS NEPHRITIS
INTRODUCTION AND AIMS: Proliferative lupus nephritis (LN) can potentially progress to renal failure. Little is known about the pathogenesis of proliferative processes that lead to irreversible glomerular damage. Metalloproteins especially matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) play an important role in maintaining homeostasis of extracellular matrix in the glomeruli. We examined the serum concentration of s-RAGE, EN-RAGE, HMGB1, PAPP-a, MMP-2, 3, 7, 9, TIMP-1, TIMP-2, S100A8, S100A9, to distinguish between the focal and diffuse form of proliferative LN.
- Open Access
- 30 August 2017
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 42 (3) , 509-518
Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis
Background: Pregnancy-associated plasma protein A (PAPP-A) is associated with adverse outcome of long-term hemodialysis patients (HD). The aim of the study was to test whether its homolog pregnancy-associated plasma protein A2 (PAPP-A2) can be detected in serum of HD patients and to define its significance. Methods: The studied group consisted of 102 long-term HD patients and 25 healthy controls. HD patients were prospectively followed up for five years (2009-2014). PAPP-A2 was measured by surface plasmon resonance biosensor, PAPP-A by time resolved amplified cryptate emission. Results: PAPP-A2, similarly as PAPP-A, was significantly increased in HD patients (median (interquartile range)) PAPP-A2: 6.2 (2.6-10.8) ng/mL, vs. 3.0 (0.7-5.9) ng/mL, p=0.006; PAPP-A: 18.9 (14.3-23.4) mIU/L, vs. 9.5 (8.4-10.5) mIU/L, pConclusion: PAPP-A2 is increased in HD patients and interacts with PAPP-A on patients´ prognosis.
- 30 August 2017
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 42 (3) , 509-518
Open AccessPregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis
Background: Pregnancy-associated plasma protein A (PAPP-A) is associated with adverse outcome of long-term hemodialysis patients (HD). The aim of the study was to test whether its homolog pregnancy-associated plasma protein A2 (PAPP-A2) can be detected in serum of HD patients and to define its significance. Methods: The studied group consisted of 102 long-term HD patients and 25 healthy controls. HD patients were prospectively followed up for five years (2009-2014). PAPP-A2 was measured by surface plasmon resonance biosensor, PAPP-A by time resolved amplified cryptate emission. Results: PAPP-A2, similarly as PAPP-A, was significantly increased in HD patients (median (interquartile range)) PAPP-A2: 6.2 (2.6-10.8) ng/mL, vs. 3.0 (0.7-5.9) ng/mL, p=0.006; PAPP-A: 18.9 (14.3-23.4) mIU/L, vs. 9.5 (8.4-10.5) mIU/L, pConclusion: PAPP-A2 is increased in HD patients and interacts with PAPP-A on patients´ prognosis.
- 26 June 2015
- Published by Care Comm in Gastroenterologie a hepatologie
- Vol. 69 (3) , 262-266
Trombotic microangiopathy – a nephrologists‘ view
- 26 June 2015
- Published by Care Comm in Gastroenterologie a hepatologie
- Vol. 69 (3) , 262-266
Trombotic microangiopathy – a nephrologists‘ view
- Open Access
- 21 May 2015
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (suppl_3) , iii108
FP124MATRIX METALLOPROTEINASES (MMP-2, 3, 7, 9) AND THEIR TISSUE INHIBITORS (TIMP-1, 2) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Introduction and Aims: Systemic lupus erythematosus (SLE) is an autoimmune disease that involves multiple organs including kidney and is characterised by persistent systemic inflammation. Among the effects of inflammatory mediators, the induction of matrix metalloproteinases (MMPs) has been suggested to be important in the development of SLE and organ involvement. In this study, we investigated the serum levels of MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, and TIMP-2 in patients with SLE and healthy controls.
- 21 May 2015
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (suppl_3) , iii108
Open AccessFP124MATRIX METALLOPROTEINASES (MMP-2, 3, 7, 9) AND THEIR TISSUE INHIBITORS (TIMP-1, 2) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Introduction and Aims: Systemic lupus erythematosus (SLE) is an autoimmune disease that involves multiple organs including kidney and is characterised by persistent systemic inflammation. Among the effects of inflammatory mediators, the induction of matrix metalloproteinases (MMPs) has been suggested to be important in the development of SLE and organ involvement. In this study, we investigated the serum levels of MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, and TIMP-2 in patients with SLE and healthy controls.